Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KERENDIA vs ANEXSIA 7.5/325
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR). It binds to the MR and inhibits the recruitment of coactivators, thereby reducing the expression of pro-inflammatory and pro-fibrotic mediators in the kidney and heart.
Hydrocodone is a mu-opioid receptor agonist, producing analgesia and euphoria. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and providing analgesic and antipyretic effects.
To reduce the risk of sustained e GFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes.
Management of moderate to moderately severe pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate
10 mg orally once daily initially, then titrate to 20 mg once daily after 4 weeks if tolerated.
1 tablet (hydrocodone 7.5 mg / acetaminophen 325 mg) orally every 4 to 6 hours as needed for pain; maximum 6 tablets per day (hydrocodone 45 mg / acetaminophen 1950 mg).
The terminal elimination half-life is approximately 2–4 hours in healthy subjects. In patients with renal impairment, the half-life may be prolonged up to 6–8 hours, allowing for once-daily dosing in chronic kidney disease.
Hydrocodone: 3.8-4.5 hours (immediate-release). Acetaminophen: 2-3 hours. Clinical note: Half-life prolonged in hepatic impairment; requires dose adjustment.
Primarily metabolized by CYP3A4 (≈90%) and to a lesser extent by CYP2C8 (≈10%). No active metabolites.
Hydrocodone: CYP3A4 and CYP2D6; Acetaminophen: primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation, with minor oxidation by CYP2E1.
Approximately 80% of the dose is eliminated via feces (primarily as unchanged drug) and ~20% via urine (mostly as metabolites). Renal excretion of unchanged drug is minimal (less than 1%).
Renal: ~90-100% as hydrocodone metabolites (conjugated) and unchanged hydrocodone; ~60% as acetaminophen metabolites (glucuronide, sulfate, cysteine); <5% unchanged acetaminophen. Biliary/fecal: <5%.
Approximately 92% bound to plasma proteins, primarily albumin and alpha-1 acid glycoprotein.
Hydrocodone: ~20-30% (albumin). Acetaminophen: ~10-25% (albumin).
The apparent volume of distribution is approximately 50 L (about 0.7 L/kg in a 70 kg adult), indicating moderate tissue distribution, likely into kidney and heart tissues.
Hydrocodone: 3-4 L/kg (extensive tissue distribution). Acetaminophen: ~1 L/kg (uniformly distributed).
Oral bioavailability is about 90–95% in healthy subjects, indicating nearly complete absorption after oral administration. Food does not significantly affect absorption.
Oral: Hydrocodone ~70% (high first-pass metabolism); Acetaminophen ~85-90% (minimal first-pass).
e GFR 25-59 m L/min/1.73 m²: Initiate 10 mg once daily; continue 10 mg if tolerated. e GFR <25 m L/min: Not recommended.
For GFR 30-59 m L/min: administer every 6 hours; maximum 4 tablets per day. For GFR 15-29 m L/min: administer every 8 hours; maximum 3 tablets per day. For GFR <15 m L/min: not recommended due to accumulation of metabolites.
Child-Pugh B (moderate impairment): 10 mg once daily. Child-Pugh C (severe impairment): Not recommended.
Child-Pugh Class A: no adjustment necessary. Child-Pugh Class B: reduce dose by 25-50% and extend dosing interval to every 6-8 hours; maximum 4 tablets per day. Child-Pugh Class C: contraindicated due to risk of hepatotoxicity.
Safety and efficacy not established in pediatric patients.
Not recommended for pediatric patients; safety and efficacy not established for children under 18 years. For adolescents ≥18 years: adult dosing.
No specific dose adjustment required; monitor renal function closely.
Initiate at 1 tablet (hydrocodone 5 mg / acetaminophen 325 mg) every 6 hours as needed; titrate cautiously due to increased sensitivity, decreased renal function, and risk of respiratory depression. Maximum 4 tablets per day.
No FDA boxed warning.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity due to acetaminophen.
Hyperkalemia: Monitor serum potassium levels; may require dose adjustment or discontinuation.,Hypotension: Risk increased in patients with volume depletion or concomitant antihypertensive therapy.,Acute kidney injury: Monitor renal function; consider temporary discontinuation in setting of significant renal impairment.,Hepatic impairment: Not recommended in patients with severe hepatic impairment (Child-Pugh C).
Risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use of alcohol, benzodiazepines, or other CNS depressants; hepatotoxicity; severe hypotension; adrenal insufficiency; seizures; GI obstruction; impaired mental/physical abilities; use in elderly, cachectic, or debilitated patients; renal impairment; hepatic impairment; pregnancy; labor and delivery; nursing mothers; pediatric use; driving and operating machinery.
Concomitant use with strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ketoconazole, ritonavir).,Addison's disease (adrenal insufficiency).,Serum potassium > 5.0 m Eq/L at initiation.
Significant respiratory depression; acute or severe bronchial asthma; known or suspected GI obstruction; hypersensitivity to hydrocodone or acetaminophen; concomitant use of MAOIs or within 14 days of such therapy.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and may increase finerenone exposure. No other food interactions noted.
Avoid alcohol consumption due to increased risk of acetaminophen hepatotoxicity and CNS depression. No specific food restrictions, but grapefruit juice may theoretically affect hydrocodone metabolism via CYP3A4 inhibition; however, clinical significance is uncertain.
Based on animal studies, Kerendia (finerenone) is associated with fetal harm. In rats, embryofetal toxicity (reduced fetal weights, delayed ossification) and malformations (cardiovascular, skeletal) were observed at maternal exposures below the maximum recommended human dose. In rabbits, increased post-implantation loss and decreased fetal weights occurred. There are no adequate human studies. Use is contraindicated in pregnancy. Avoid in women of childbearing potential not using effective contraception.
FDA Category C (hydrocodone) and Category D (acetaminophen) in third trimester. First trimester: Acetaminophen associated with rare gastroschisis; hydrocodone risk of neural tube defects. Second trimester: No major malformations except with prolonged opioid use. Third trimester: Acetaminophen safe; hydrocodone risk of neonatal opioid withdrawal syndrome (NOWS). Avoid near term.
No data on presence in human milk, effects on breastfed infant, or milk production. Excreted in rat milk. M/P ratio unknown. Due to potential for serious adverse reactions (e.g., hyperkalemia, hypotension), breastfeeding is not recommended during therapy and for 1 week after last dose.
Hydrocodone/acetaminophen excreted in breast milk. M/P ratio unknown. Hydrocodone relative infant dose <3% of weight-adjusted maternal dose. Acetaminophen relative infant dose <2%. Use with caution; monitor infant for sedation, apnea, poor feeding. Highest risk in CYP2D6 ultrarapid metabolizers.
Kerendia is contraindicated in pregnancy. No dose adjustments are provided due to lack of human data; use is not recommended. Pharmacokinetic changes in pregnancy are unknown, but dose modifications are not applicable as therapy should be discontinued if pregnancy occurs.
Increased clearance of hydrocodone in pregnancy may require dose adjustment; monitor for inadequate analgesia. Acetaminophen pharmacokinetics unchanged. Avoid high doses (hepatotoxicity risk). Consider baseline hepatic function. No specific dose adjustment recommended; titrate to effect.
Monitor serum potassium closely, especially in patients with e GFR <30 m L/min/1.73m² or baseline K+ >5.0 m Eq/L. Avoid use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir). Contraindicated with concomitant mineralocorticoid receptor antagonists (e.g., spironolactone, eplerenone). Use caution with moderate CYP3A4 inhibitors (e.g., erythromycin, verapamil) and moderate CYP3A4 inducers (e.g., rifampin, phenytoin). Assess e GFR and serum potassium before initiation and at 1 month after starting or adjusting dose.
ANEXSIA 7.5/325 (hydrocodone/acetaminophen) carries a boxed warning for acetaminophen hepatotoxicity; maximum acetaminophen dose from all sources should not exceed 4 g/day. Hydrocodone is metabolized by CYP2D6 to hydromorphone; ultrarapid metabolizers may experience toxicity. Avoid concurrent use with other CNS depressants including alcohol. Prescribe with caution in patients with renal impairment (hydrocodone accumulation) or hepatic impairment (acetaminophen toxicity). Monitor for signs of respiratory depression, especially at therapy initiation and dose titration. Use the lowest effective dose for the shortest duration.
Take this medication exactly as prescribed, usually once daily with or without food.,Do not use potassium supplements or salt substitutes containing potassium without consulting your doctor.,Report symptoms of hyperkalemia (e.g., muscle weakness, fatigue, palpitations, numbness) immediately.,Avoid grapefruit and grapefruit juice during treatment.,Inform all healthcare providers that you are taking KERENDIA (finerenone).,Do not stop taking KERENDIA without talking to your doctor.,Store at room temperature, away from moisture and heat.
Do not exceed 6 tablets per day due to acetaminophen content.,Avoid alcohol while taking this medication.,Do not drive or operate heavy machinery until you know how this medication affects you.,Take exactly as prescribed; do not share with others.,Seek emergency help if you experience difficulty breathing, severe drowsiness, or signs of allergic reaction.,Store securely out of reach of children and dispose of unused medication properly.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KERENDIA vs ANEXSIA 7.5/325, answered by our medical review team.
KERENDIA is a Mineralocorticoid Receptor Antagonist that works by Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR). It binds to the MR and inhibits the recruitment of coactivators, thereby reducing the expression of pro-inflammatory and pro-fibrotic mediators in the kidney and heart.. ANEXSIA 7.5/325 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist, producing analgesia and euphoria. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and providing analgesic and antipyretic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KERENDIA and ANEXSIA 7.5/325 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KERENDIA is: 10 mg orally once daily initially, then titrate to 20 mg once daily after 4 weeks if tolerated.. The standard adult dose of ANEXSIA 7.5/325 is: 1 tablet (hydrocodone 7.5 mg / acetaminophen 325 mg) orally every 4 to 6 hours as needed for pain; maximum 6 tablets per day (hydrocodone 45 mg / acetaminophen 1950 mg).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KERENDIA and ANEXSIA 7.5/325 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KERENDIA is classified as Category C. Based on animal studies, Kerendia (finerenone) is associated with fetal harm. In rats, embryofetal toxicity (reduced fetal weights, delayed ossification) and malformations (cardiov. ANEXSIA 7.5/325 is classified as Category C. FDA Category C (hydrocodone) and Category D (acetaminophen) in third trimester. First trimester: Acetaminophen associated with rare gastroschisis; hydrocodone risk of neural tube d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.